Abstract:Genetic variation in the lysosomal and transmembrane protein 106B (TMEM106B) modifies risk for a diverse range of neurodegenerative disorders, especially frontotemporal lobar degeneration (FTLD) with progranulin (PGRN) haplo-insufficiency, although the molecular mechanisms involved are not yet understood. Through advances in cryo-electron microscopy (cryo-EM), homotypic aggregates of the C-Terminal domain of TMEM106B (TMEM CT) were discovered as a previously unidentified cytosolic proteinopathy in the brains of FTLD, Alzheimers disease, progressive supranuclear palsy (PSP), and dementia with Lewy bodies (DLB) patients. While it remains unknown what role TMEM CT aggregation plays in neuronal loss, its presence across a range of aging related dementia disorders indicates involvement in multi-proteinopathy driven neurodegeneration. To determine the TMEM CT aggregation propensity and neurodegenerative potential, we characterized a novel transgenic C. elegans model expressing the human TMEM CT fragment constituting the fibrillar core seen in FTLD cases. We found that pan-neuronal expression of human TMEM CT in C. elegans causes neuronal dysfunction as evidenced by behavioral analysis. Cytosolic aggregation of TMEM CT proteins accompanied the behavioral dysfunction driving neurodegeneration, as illustrated by loss of GABAergic neurons. To investigate the molecular mechanisms driving TMEM106B proteinopathy, we explored the impact of PGRN loss on the neurodegenerative effect of TMEM CT expression. To this end, we generated TMEM CT expressing C. elegans with loss of pgrn-1, the C. elegans ortholog of human PGRN. Neither full nor partial loss of pgrn-1 altered the motor phenotype of our TMEM CT model suggesting TMEM CT aggregation occurs downstream of PGRN loss of function. We also tested the ability of genetic suppressors of tauopathy to rescue TMEM CT pathology. We found that genetic knockout of spop-1, sut-2, and sut-6 resulted in weak to no rescue of proteinopathy phenotypes, indicating that the mechanistic drivers of TMEM106B proteinopathy may be distinct from tauopathy. Taken together, our data demonstrate that TMEM CT aggregation can kill neurons. Further, expression of TMEM CT in C. elegans neurons provides a useful model for the functional characterization of TMEM106B proteinopathy in neurodegenerative disease.

Tracing TMEM106B Fibril Deposition in Aging and Parkinson’s Disease with Dementia Brains

Newly identified transmembrane protein 106B amyloid fibrils in the human brain: pathogens or by-products?

Age-dependent formation of TMEM106B amyloid filaments in human brains

Generic amyloid fibrillation of TMEM106B in patient with Parkinson’s disease dementia and normal elders

Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging

Physiological and pathological functions of TMEM106B in neurodegenerative diseases

Characterization of Local White Matter Microstructural Alterations in Alzheimer’s Disease: A Reproducible Study

TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia

Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease

Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders

TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy.

Amyloid fibrils in disease FTLD-TDP are composed of TMEM106B not TDP-43

Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 mice

TMEM16F regulates pathologic α‐synuclein secretion and spread in cellular and mouse models of Parkinson's disease

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

TMEM106B aggregation in neurodegenerative diseases: linking genetics to function

Distinct fiber-specific white matter reductions pattern in early- and late-onset Alzheimer’s disease

Distinct fiber-specific white matter reductions pattern in early- and late-onset Alzheimer's disease

Controversy of TMEM230 Associated with Parkinson’s Disease

Rs1990622 Variant Associates with Alzheimer's Disease and Regulates TMEM106B Expression in Human Brain Tissues.

TMEM16F may be a new therapeutic target for Alzheimer’s disease